Affordable Access

Successful use of anti-CD20 (rituximab) in severe, life-threatening childhood immune thrombocytopenic purpura.

Authors
Type
Published Article
Journal
The Journal of Pediatrics
0022-3476
Publisher
Elsevier
Publication Date
Volume
143
Issue
5
Pages
670–673
Identifiers
PMID: 14615744
Source
Medline

Abstract

Thrombocytopenia with life-threatening hemorrhage in childhood immune thrombocytopenic purpura is rare, but effective therapeutic options are limited for the patient with bleeding. We report the efficacy of humanized anti-CD20 monoclonal antibody (rituximab, Rituxan) therapy for an infant with severe, refractory life-threatening immune thrombocytopenic purpura.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments